Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2021)

Historic Capital Expenditures for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to $333000.0.

  • Black Diamond Therapeutics' Capital Expenditures rose 20550.46% to $333000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $2.7 million, marking a year-over-year increase of 180845.07%. This contributed to the annual value of $33000.0 for FY2023, which is 8281.25% down from last year.
  • Per Black Diamond Therapeutics' latest filing, its Capital Expenditures stood at $333000.0 for Q4 2021, which was up 20550.46% from $1.2 million recorded in Q3 2021.
  • In the past 5 years, Black Diamond Therapeutics' Capital Expenditures registered a high of $1.2 million during Q3 2021, and its lowest value of -$2000.0 during Q2 2019.
  • In the last 3 years, Black Diamond Therapeutics' Capital Expenditures had a median value of $25000.0 in 2020 and averaged $261181.8.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Capital Expenditures tumbled by 2727.27% in 2020, and later surged by 1462500.0% in 2021.
  • Over the past 3 years, Black Diamond Therapeutics' Capital Expenditures (Quarter) stood at $2000.0 in 2019, then surged by 5350.0% to $109000.0 in 2020, then surged by 205.5% to $333000.0 in 2021.
  • Its Capital Expenditures was $333000.0 in Q4 2021, compared to $1.2 million in Q3 2021 and $814000.0 in Q2 2021.